#ensitrelvir — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #ensitrelvir, aggregated by home.social.
-
@feisty_lemming
Yes, the 9% stated by the article (from the international study) is very low. But that is good news, right? Even without any drug, the chance of catching an infection from another infected person in your same living space is very low.From the study you shared, I see many of the vaccinated got sick from what they were supposedly vaccinated for!
-
@feisty_lemming
Yes, the 9% stated by the article (from the international study) is very low. But that is good news, right? Even without any drug, the chance of catching an infection from another infected person in your same living space is very low.From the study you shared, I see many of the vaccinated got sick from what they were supposedly vaccinated for!
-
@feisty_lemming
Yes, the 9% stated by the article (from the international study) is very low. But that is good news, right? Even without any drug, the chance of catching an infection from another infected person in your same living space is very low.From the study you shared, I see many of the vaccinated got sick from what they were supposedly vaccinated for!
-
@feisty_lemming
Yes, the 9% stated by the article (from the international study) is very low. But that is good news, right? Even without any drug, the chance of catching an infection from another infected person in your same living space is very low.From the study you shared, I see many of the vaccinated got sick from what they were supposedly vaccinated for!
-
@feisty_lemming
Yes, the 9% stated by the article (from the international study) is very low. But that is good news, right? Even without any drug, the chance of catching an infection from another infected person in your same living space is very low.From the study you shared, I see many of the vaccinated got sick from what they were supposedly vaccinated for!
-
@mikemccaffrey
According to their trial, without the drug, only 9% of people living in the same house with a symptomatic person also get sick. So your odds of getting sick are already very low. With the drug, 3% get sick, so your odds are not zero."9% of people who received a placebo within 72 hours of a housemate developing symptoms became symptomatic themselves, compared with only about 3% of those who got a five-day course of #ensitrelvir."
Is this drug worth the side effects?
-
@mikemccaffrey
According to their trial, without the drug, only 9% of people living in the same house with a symptomatic person also get sick. So your odds of getting sick are already very low. With the drug, 3% get sick, so your odds are not zero."9% of people who received a placebo within 72 hours of a housemate developing symptoms became symptomatic themselves, compared with only about 3% of those who got a five-day course of #ensitrelvir."
Is this drug worth the side effects?
-
@mikemccaffrey
According to their trial, without the drug, only 9% of people living in the same house with a symptomatic person also get sick. So your odds of getting sick are already very low. With the drug, 3% get sick, so your odds are not zero."9% of people who received a placebo within 72 hours of a housemate developing symptoms became symptomatic themselves, compared with only about 3% of those who got a five-day course of #ensitrelvir."
Is this drug worth the side effects?
-
@mikemccaffrey
According to their trial, without the drug, only 9% of people living in the same house with a symptomatic person also get sick. So your odds of getting sick are already very low. With the drug, 3% get sick, so your odds are not zero."9% of people who received a placebo within 72 hours of a housemate developing symptoms became symptomatic themselves, compared with only about 3% of those who got a five-day course of #ensitrelvir."
Is this drug worth the side effects?
-
@mikemccaffrey
According to their trial, without the drug, only 9% of people living in the same house with a symptomatic person also get sick. So your odds of getting sick are already very low. With the drug, 3% get sick, so your odds are not zero."9% of people who received a placebo within 72 hours of a housemate developing symptoms became symptomatic themselves, compared with only about 3% of those who got a five-day course of #ensitrelvir."
Is this drug worth the side effects?
-
Ensitrelvir Pill Reduces COVID-19 Infection Risk After Exposure
A phase 3 trial of the drug ensitrelvir, known as Xocova, showed a 67% reduction in COVID-19 infection risk for people treated after exposure.
https://newsnews.ai/article/ensitrelvir-pill-prevents-covid-after-exposure
-
#Ensitrelvir for the #treatment of hospitalized adults with #COVID19: an international phase 3 randomized placebo-controlled trial, https://etidiohnew.blogspot.com/2026/04/ensitrelvir-for-treatment-of.html
-
#Ensitrelvir for the #treatment of hospitalized adults with #COVID19: an international phase 3 randomized placebo-controlled trial, https://etidiohnew.blogspot.com/2026/04/ensitrelvir-for-treatment-of.html
-
#Ensitrelvir for the #treatment of hospitalized adults with #COVID19: an international phase 3 randomized placebo-controlled trial, https://etidiohnew.blogspot.com/2026/04/ensitrelvir-for-treatment-of.html
-
#Ensitrelvir for the #treatment of hospitalized adults with #COVID19: an international phase 3 randomized placebo-controlled trial, https://etidiohnew.blogspot.com/2026/04/ensitrelvir-for-treatment-of.html
-
#Ensitrelvir for the #treatment of hospitalized adults with #COVID19: an international phase 3 randomized placebo-controlled trial, https://etidiohnew.blogspot.com/2026/04/ensitrelvir-for-treatment-of.html
-
#Antiviral efficacy of oral #ensitrelvir versus oral ritonavir-boosted #nirmatrelvir in #COVID19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial, https://etidiohnew.blogspot.com/2025/10/antiviral-efficacy-of-oral-ensitrelvir.html
-
#Antiviral efficacy of oral #ensitrelvir versus oral ritonavir-boosted #nirmatrelvir in #COVID19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial, https://etidiohnew.blogspot.com/2025/10/antiviral-efficacy-of-oral-ensitrelvir.html
-
#Antiviral efficacy of oral #ensitrelvir versus oral ritonavir-boosted #nirmatrelvir in #COVID19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial, https://etidiohnew.blogspot.com/2025/10/antiviral-efficacy-of-oral-ensitrelvir.html
-
#Antiviral efficacy of oral #ensitrelvir versus oral ritonavir-boosted #nirmatrelvir in #COVID19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial, https://etidiohnew.blogspot.com/2025/10/antiviral-efficacy-of-oral-ensitrelvir.html
-
#Antiviral efficacy of oral #ensitrelvir versus oral ritonavir-boosted #nirmatrelvir in #COVID19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial, https://etidiohnew.blogspot.com/2025/10/antiviral-efficacy-of-oral-ensitrelvir.html
-
Sporadic Occurrence of #Ensitrelvir #Resistant #SarsCoV2 #Japan, Emerg Infect Dis.: https://wwwnc.cdc.gov/eid/article/30/6/24-0023_article
Using the GISAID EpiCoV database, we identified 256 #COVID19 patients in Japan during March 31–December 31, 2023, who had mutations in the SARS-CoV-2 #NS5 conferring ensitrelvir resistance.
-
Sporadic Occurrence of #Ensitrelvir #Resistant #SarsCoV2 #Japan, Emerg Infect Dis.: https://wwwnc.cdc.gov/eid/article/30/6/24-0023_article
Using the GISAID EpiCoV database, we identified 256 #COVID19 patients in Japan during March 31–December 31, 2023, who had mutations in the SARS-CoV-2 #NS5 conferring ensitrelvir resistance.
-
Sporadic Occurrence of #Ensitrelvir #Resistant #SarsCoV2 #Japan, Emerg Infect Dis.: https://wwwnc.cdc.gov/eid/article/30/6/24-0023_article
Using the GISAID EpiCoV database, we identified 256 #COVID19 patients in Japan during March 31–December 31, 2023, who had mutations in the SARS-CoV-2 #NS5 conferring ensitrelvir resistance.
-
Sporadic Occurrence of #Ensitrelvir #Resistant #SarsCoV2 #Japan, Emerg Infect Dis.: https://wwwnc.cdc.gov/eid/article/30/6/24-0023_article
Using the GISAID EpiCoV database, we identified 256 #COVID19 patients in Japan during March 31–December 31, 2023, who had mutations in the SARS-CoV-2 #NS5 conferring ensitrelvir resistance.
-
Sporadic Occurrence of #Ensitrelvir #Resistant #SarsCoV2 #Japan, Emerg Infect Dis.: https://wwwnc.cdc.gov/eid/article/30/6/24-0023_article
Using the GISAID EpiCoV database, we identified 256 #COVID19 patients in Japan during March 31–December 31, 2023, who had mutations in the SARS-CoV-2 #NS5 conferring ensitrelvir resistance.
-
''#Ensitrelvir #treatment of hamsters infected with the virus possessing Nsp5-M49L/E166A was ineffective; however, #nirmatrelvir or #molnupiravir treatment was effective. Therefore, it is important to closely monitor the emergence of ensitrelvir-resistant SARS-CoV-2 variants to guide antiviral treatment selection.''
-
''#Ensitrelvir #treatment of hamsters infected with the virus possessing Nsp5-M49L/E166A was ineffective; however, #nirmatrelvir or #molnupiravir treatment was effective. Therefore, it is important to closely monitor the emergence of ensitrelvir-resistant SARS-CoV-2 variants to guide antiviral treatment selection.''
-
''#Ensitrelvir #treatment of hamsters infected with the virus possessing Nsp5-M49L/E166A was ineffective; however, #nirmatrelvir or #molnupiravir treatment was effective. Therefore, it is important to closely monitor the emergence of ensitrelvir-resistant SARS-CoV-2 variants to guide antiviral treatment selection.''
-
In vitro and in vivo characterization of #SARS-CoV-2 #resistance to #ensitrelvir https://www.nature.com/articles/s41467-023-40018-1 #antivirals #research #science #pharmacology
-
In vitro and in vivo characterization of #SARS-CoV-2 #resistance to #ensitrelvir https://www.nature.com/articles/s41467-023-40018-1 #antivirals #research #science #pharmacology
-
In vitro and in vivo characterization of #SARS-CoV-2 #resistance to #ensitrelvir https://www.nature.com/articles/s41467-023-40018-1 #antivirals #research #science #pharmacology
-
COVID pill is first to cut short positive-test time after infection
https://www.nature.com/articles/d41586-023-00548-6
"The antiviral ensitrelvir, which is not approved in the United States, shortens symptoms in people with mild COVID and might reduce risk of long COVID — but more data are needed."
#Covid #Ensitrelvir #LongCovid -
COVID pill is first to cut short positive-test time after infection
https://www.nature.com/articles/d41586-023-00548-6
"The antiviral ensitrelvir, which is not approved in the United States, shortens symptoms in people with mild COVID and might reduce risk of long COVID — but more data are needed."
#Covid #Ensitrelvir #LongCovid -
COVID pill is first to cut short positive-test time after infection
https://www.nature.com/articles/d41586-023-00548-6
"The antiviral ensitrelvir, which is not approved in the United States, shortens symptoms in people with mild COVID and might reduce risk of long COVID — but more data are needed."
#Covid #Ensitrelvir #LongCovid -
COVID pill is first to cut short positive-test time after infection
https://www.nature.com/articles/d41586-023-00548-6
"The antiviral ensitrelvir, which is not approved in the United States, shortens symptoms in people with mild COVID and might reduce risk of long COVID — but more data are needed."
#Covid #Ensitrelvir #LongCovid -
COVID pill is first to cut short positive-test time after infection
https://www.nature.com/articles/d41586-023-00548-6
"The antiviral ensitrelvir, which is not approved in the United States, shortens symptoms in people with mild COVID and might reduce risk of long COVID — but more data are needed."
#Covid #Ensitrelvir #LongCovid -
#Efficacy #comparison of #3CLpro #inhibitors #ensitrelvir and #nirmatrelvir against #SARS-CoV-2 in vitro and in vivo https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkad027/7033725?rss=1
-
#上海医药 获得抗新冠病毒口服药物#Ensitrelvir 独家进口及经销权
https://company.cnstock.com/company/scp_gsxw/202212/4997431.htm新冠口服药！#盐野义 3CL蛋白酶抑制剂#Xocova 获日本紧急批准：治疗轻中度COVID-19!
https://news.bioon.com/article/3eade499910e.html -
#上海医药 获得抗新冠病毒口服药物#Ensitrelvir 独家进口及经销权
https://company.cnstock.com/company/scp_gsxw/202212/4997431.htm新冠口服药！#盐野义 3CL蛋白酶抑制剂#Xocova 获日本紧急批准：治疗轻中度COVID-19!
https://news.bioon.com/article/3eade499910e.html
